<DOC>
	<DOCNO>NCT00542490</DOCNO>
	<brief_summary>The purpose study determine progression-free survival patient surgically stag , Stage I-II papillary serous , clear cell , endometrioid carcinoma high-intermediate risk factor treat vaginal cuff brachytherapy follow chemotherapy .</brief_summary>
	<brief_title>Vaginal Cuff Brachytherapy Followed Chemotherapy Patients With Endometrioid Cancer</brief_title>
	<detailed_description>All patient must undergo complete surgical stag include bilateral pelvic para-aortic lymphadenectomy . All patient receive radiation therapy . Treatment deliver either LDR HDR brachytherapy . The treatment plan must start time enrollment . The vaginal brachytherapy start within 4 week surgery ( within 2 week enrollment ) , order avoid delay initiation systemic therapy , start post-operative day 21 . The dose prescribed vaginal ( mucosal ) surface define surface applicator . Following vaginal cuff radiation therapy , patient receive chemotherapy .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>All patient must undergo specified complete surgical staging . Patients must surgically stag endometrial cancer patient highrisk recurrence . Patients must adequate bone marrow , renal hepatic function . Patients recurrent disease . Patients GOG performance status 3 4 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Endometrial cancer</keyword>
	<keyword>Gynecologic Cancer</keyword>
	<keyword>Vaginal Cuff Brachytherapy</keyword>
	<keyword>Vaginal radiation</keyword>
</DOC>